International Journal of Cardiology
Volume 139, Issue 1 , Pages 75-79 , 18 February 2010

Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure

Received 28 June 2008 ,Accepted 1 October 2008.

References 

  1. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196–202
  2. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422–1432
  3. Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Program and abstracts from the American Heart Association Scientific Sessions 2005; November 13–16, 2005; Dallas, Texas. Late Breaking Clinical Trials II.
  4. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883–1891
  5. Parissis JT, Farmakis D, Bistola V, Adamopoulos S, Kremastinos DT. Levosimendan for the treatment of acute heart failure syndromes: time to identify subpopulations of responding patients. Am J Cardiol. 2007;99:146–147
  6. De Luca L, Mebazaa A, Filippatos G, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail. 2008;10:201–213
  7. Mebazaa A, Gheorghiade M, Piña IL, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008;36(1 Suppl):S129–S139
  8. Gheorghiade M, Zannad F, Sopko G, et al. International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958–3968
  9. Nieminen MS, Bohm M, Cowie MR, et al. ESC Committee for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384–416
  10. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216
  11. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43–51
  12. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–463
  13. Zannad F, Mebazaa A, Juilliere Y, et al. Clinical profile, contemporary management and one year mortality in patients with severe acute heart failure syndromes: the EFICA study. Eur J Heart Fail. 2006;8:697–705
  14. Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev. 2007;12:149–156
  15. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138:78–86
  16. Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547
  17. Parissis JT, Filippatos G, Farmakis D, et al. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother. 2005;6:2741–2751
  18. Parissis JT, Panou F, Farmakis D, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol. 2005;96:423–426
  19. Parissis JT, Paraskevaidis I, Bistola V, et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol. 2006;98:1489–1492
  20. Parissis JT, Karavidas A, Bistola V, Arapi S, Paraskevaidis IA, Farmakis D, et al. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis. 2008;197:278–282
  21. Adamopoulos S, Parissis JT, Iliodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol. 2006;98:102–106
  22. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357–2368
  23. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49:1733–1739
  24. Giannakoulas G, Giannoglou G, Vassilikos V, et al. Clinical significance of acute neurohormonal response after levosimendan treatment. Am J Cardiol. 2006;98:1123–1124
  25. Parissis JT, Adamopoulos S, Farmakis D, et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart. 2006;92:1768–1772
  26. Coats AJ. Ethical authorship and publishing. Int J Cardiol. 2009;131:149–150

PII: S0167-5273(08)01053-X

doi: 10.1016/j.ijcard.2008.10.003

International Journal of Cardiology
Volume 139, Issue 1 , Pages 75-79 , 18 February 2010

Article Tools

* Image Usage & Resolution